Seres Therapeutics Inc

MCRB

Company Profile

  • Business description

    Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

  • Contact

    101 Cambridgepark Drive
    CambridgeMA02140
    USA

    T: +1 617 945-9626

    E: [email protected]

    https://www.serestherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    103

Stocks News & Analysis

stocks

Acquisition a sign of weakness for overvalued ASX share

Acquisition unlikely to improve prospects in the US and detracts from other opportunities.
stocks

ASX opportunities after earnings season

Finding value in an expensive market.
stocks

3 global ‘buy the dip’ candidates with wide moats

Does recent share price weakness spell opportunity in these three high-quality companies? Our analysts think so.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,120.9034.100.38%
CAC 407,896.9371.690.92%
DAX 4023,748.8650.710.21%
Dow JONES (US)45,819.3114.91-0.03%
FTSE 1009,277.036.26-0.07%
HKSE26,446.5658.400.22%
NASDAQ22,326.62185.520.84%
Nikkei 22544,768.12395.620.89%
NZX 50 Index13,208.3119.59-0.15%
S&P 5006,610.1425.850.39%
S&P/ASX 2008,853.0031.600.36%
SSE Composite Index3,860.5010.09-0.26%

Market Movers